SCHEMBL3366732

SCHEMBL3366732

C=CCCC(=O)N1CCCC1c1nnc(-c2ccccc2)o1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 8/20 0.52
HCRTR2 O43614 8/20 0.52
USP30 Q70CQ3 1/20 0.45
DPP4 P27487 1/20 0.45
NPC1 O15118 4/20 0.42
RAB9A P51151 4/20 0.42
HSD11B1 P28845 2/20 0.41
MEN1 O00255 2/20 0.41
ALDH1A1 P00352 2/20 0.41
KMT2A Q03164 2/20 0.41
PKM P14618 2/20 0.41
KDM4E B2RXH2 1/20 0.41
TNKS O95271 1/20 0.41
PARP1 P09874 1/20 0.41
PARP2 Q9UGN5 1/20 0.41
LMNA P02545 1/20 0.41
TSHR P16473 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3369944 0.90 HSD11B1 (0.50) HCRTR1HCRTR2NPC1RAB9AHSD11B1
SCHEMBL3364808 0.86 HCRTR1 (0.49) HCRTR1HCRTR2DPP4NPC1RAB9A
SCHEMBL3370192 0.84 HCRTR1 (0.52) HCRTR1HCRTR2USP30DPP4NPC1
SCHEMBL3366080 0.83 HCRTR1 (0.55) HCRTR1HCRTR2USP30DPP4NPC1
SCHEMBL3370370 0.82 HCRTR1 (0.60) HCRTR1HCRTR2USP30DPP4NPC1
SCHEMBL3369795 0.81 HCRTR1 (0.58) HCRTR1HCRTR2USP30DPP4NPC1
SCHEMBL3366778 0.80 HCRTR1 (0.58) HCRTR1HCRTR2USP30DPP4NPC1
SCHEMBL3369475 0.80 HCRTR1 (0.61) HCRTR1HCRTR2USP30DPP4NPC1
SCHEMBL6068996 0.79 HCRTR1 (0.54) HCRTR1HCRTR2USP30DPP4HSD11B1
SCHEMBL3369456 0.79 HCRTR1 (0.54) HCRTR1HCRTR2USP30DPP4NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1532141-B1 2-PYRROLIDIN-2-YL- [1,3,4]-OXADIAZOLE DERIVATIVES AND THE USE OF THE SAME AS ANTIDEPRESSANTS GRUENENTHAL GMBH (DE) 2010-10-13 EP disclosed
US-7105538-B2 2-pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants GRUENENTHAL GMBH (DE) 2006-09-12 US disclosed
US-20050187260-A1 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants GRUENENTHAL GMBH (DE) 2005-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187260-A1 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants OPRD1, OPRK1, GRIN2C HCRTR1 461/4885HCRTR2 146/4885USP30 3920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.